TriangleAcalabrutinib (NCT04404088)
Acalabrutinib trial for Ann Arbor Stage III Grade 1 Follicular Lymphoma (NCT04404088). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, CD20-positive follicular lymphoma, grade one to three-A and stage three or four, meeting criteria to start treatment. Transformed lymphoma and grade three-B disease are excluded.
The idea: combine acalabrutinib, which blocks BTK growth signaling, with immune-modifying lenalidomide and CD20-targeting rituximab. Oral acalabrutinib starts first; oral lenalidomide and rituximab infusions begin in cycle two. Treatment lasts up to thirteen twenty-eight-day cycles. Researchers measure complete remissions and safety. Pregnancy-prevention rules apply.
This phase 2 study plans 80 patients. Paolo Strati leads MD Anderson's single recruiting Houston site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.